Garson Tsang

Biochemistry, Genetics and Molecular Biology · Life Sciences

13h-index6.2kcitations28works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Degradation and Inhibitors(7), Ubiquitin and proteasome pathways(6), Chronic Myeloid Leukemia Treatments(6), Chronic Lymphocytic Leukemia Research(5), PI3K/AKT/mTOR signaling in cancer(4)

Publications28 total

Supplementary Figures & Tables from BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
2023Open Access
Data from BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
2023Open Access
Data from BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
2023Open Access
Data from Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397
2023Open Access
Supplementary Tables 1 - 6, Figures 1 - 7 from Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397
2023Open Access
Supplementary Methods from BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
2023Open Access
Supplementary Methods from BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
2023Open Access
Data from Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397
2023Open Access
Supplementary Tables 1 - 6, Figures 1 - 7 from Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397
2023Open Access
Supplementary Figures & Tables from BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
2023Open Access
Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors
JAMA Oncology·2021· 38 citedOpen Access
Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model
Nature Communications·2019· 900 citedOpen Access
BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
Cancer Discovery·2018· 135 citedOpen Access
A Mixed Type 1 and Type 2 Kinase Inhibitor That Overrides FLT3 F691 and D835 Resistance Mutations
Blood·2016· 2 cited
RAF inhibitors that evade paradoxical MAPK pathway activation
Nature·2015· 374 cited
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor
New England Journal of Medicine·2015· 571 cited
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397
Cancer Discovery·2015· 197 citedOpen Access
Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor
Proceedings of the National Academy of Sciences·2013· 95 citedOpen Access
MOLECULAR GENETICS AND GENOMICS AND KIWIFRUIT BREEDING
Acta Horticulturae·2011· 7 cited
Abstract A229: BRAF inhibitors upregulate EGFR ligands: A molecular link to RAF inhibitor-induced cutaneous squamous cell carcinomas.
Molecular Cancer Therapeutics·2011· 1 cited
page 1 of 2Next →

Frequent Co-authors

Gideon Bollag(21), Prabha N. Ibrahim(20), Wayne Spevak(20), Gaston Habets(20), Jiazhong Zhang(19), Rafe Shellooe(19), Bernice Matusow(16), Heidi Carias(16), Adhirai Marimuthu(14), Elizabeth A. Burton(12), Brian L. West(12), Marika Nespi(12), Paul Severson(11), Todd Ewing(11), Laura Sanftner(10), Songyuan Shi(10), Ben Powell(8), B. J. Powell(8), Hatice Gülçin Özer(7), Dalia El‐Gamal(7)